Santhera Pharmaceuticals BreatheDMD U.S. Expanded Access Program

In February 2018, Santhera Pharmaceuticals announced the launch of their expanded access program (EAP) for U.S. patients with Duchenne who are 10 years and older and experiencing respiratory function decline. This program offers the opportunity to obtain access to investigational idebenone, at no cost, through a network of research centers across the U.S.  Dr. Kathryn Wagner, who leads the neuromuscular program at Kennedy Krieger Hospital in Baltimore, will be one of the participating sites.

Dr. Wagner and the CureDuchenne team provided information about expanded access and compassionate use in the U.S., the BreatheDMD program, and Santhera answered questions from the community.